S&P 500   3,327.80 (-0.05%)
DOW   29,320.26 (-0.09%)
QQQ   223.59 (+0.09%)
AAPL   317.97 (-0.24%)
FB   221.32 (-0.37%)
MSFT   167.53 (+0.26%)
GOOGL   1,484.21 (+0.32%)
AMZN   1,870.49 (+0.31%)
CGC   24.45 (-1.77%)
NVDA   249.02 (-0.10%)
MU   58.79 (+1.96%)
GE   11.72 (-0.76%)
TSLA   541.17 (+6.01%)
AMD   51.15 (+0.43%)
T   38.52 (+0.36%)
ACB   2.02 (-5.16%)
F   9.19 (+0.33%)
NFLX   335.84 (-1.13%)
BAC   34.48 (-0.66%)
GILD   62.76 (-0.35%)
DIS   143.81 (-0.36%)
S&P 500   3,327.80 (-0.05%)
DOW   29,320.26 (-0.09%)
QQQ   223.59 (+0.09%)
AAPL   317.97 (-0.24%)
FB   221.32 (-0.37%)
MSFT   167.53 (+0.26%)
GOOGL   1,484.21 (+0.32%)
AMZN   1,870.49 (+0.31%)
CGC   24.45 (-1.77%)
NVDA   249.02 (-0.10%)
MU   58.79 (+1.96%)
GE   11.72 (-0.76%)
TSLA   541.17 (+6.01%)
AMD   51.15 (+0.43%)
T   38.52 (+0.36%)
ACB   2.02 (-5.16%)
F   9.19 (+0.33%)
NFLX   335.84 (-1.13%)
BAC   34.48 (-0.66%)
GILD   62.76 (-0.35%)
DIS   143.81 (-0.36%)
S&P 500   3,327.80 (-0.05%)
DOW   29,320.26 (-0.09%)
QQQ   223.59 (+0.09%)
AAPL   317.97 (-0.24%)
FB   221.32 (-0.37%)
MSFT   167.53 (+0.26%)
GOOGL   1,484.21 (+0.32%)
AMZN   1,870.49 (+0.31%)
CGC   24.45 (-1.77%)
NVDA   249.02 (-0.10%)
MU   58.79 (+1.96%)
GE   11.72 (-0.76%)
TSLA   541.17 (+6.01%)
AMD   51.15 (+0.43%)
T   38.52 (+0.36%)
ACB   2.02 (-5.16%)
F   9.19 (+0.33%)
NFLX   335.84 (-1.13%)
BAC   34.48 (-0.66%)
GILD   62.76 (-0.35%)
DIS   143.81 (-0.36%)
S&P 500   3,327.80 (-0.05%)
DOW   29,320.26 (-0.09%)
QQQ   223.59 (+0.09%)
AAPL   317.97 (-0.24%)
FB   221.32 (-0.37%)
MSFT   167.53 (+0.26%)
GOOGL   1,484.21 (+0.32%)
AMZN   1,870.49 (+0.31%)
CGC   24.45 (-1.77%)
NVDA   249.02 (-0.10%)
MU   58.79 (+1.96%)
GE   11.72 (-0.76%)
TSLA   541.17 (+6.01%)
AMD   51.15 (+0.43%)
T   38.52 (+0.36%)
ACB   2.02 (-5.16%)
F   9.19 (+0.33%)
NFLX   335.84 (-1.13%)
BAC   34.48 (-0.66%)
GILD   62.76 (-0.35%)
DIS   143.81 (-0.36%)
Log in

NASDAQ:CYCN - Cyclerion Therapeutics Stock Price, Forecast & News

$3.52
+0.27 (+8.32 %)
(As of 01/21/2020 12:56 PM ET)
Today's Range
$3.21
Now: $3.52
$3.60
50-Day Range
$1.82
MA: $2.54
$3.76
52-Week Range
$1.69
Now: $3.52
$21.00
Volume412,864 shs
Average Volume911,506 shs
Market Capitalization$96.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for Cyclerion Therapeutics Inc.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCN
CUSIPN/A
CIKN/A
Phone857-327-8778

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-115,250,000.00

Miscellaneous

EmployeesN/A
Market Cap$96.56 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive CYCN News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.


Cyclerion Therapeutics (NASDAQ:CYCN) Frequently Asked Questions

What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics Inc (NASDAQ:CYCN) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.00) EPS for the quarter. The company earned $1.40 million during the quarter. View Cyclerion Therapeutics' Earnings History.

When is Cyclerion Therapeutics' next earnings date?

Cyclerion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Cyclerion Therapeutics.

What is the consensus analysts' recommendation for Cyclerion Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cyclerion Therapeutics.

Has Cyclerion Therapeutics been receiving favorable news coverage?

Media stories about CYCN stock have trended very positive on Tuesday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyclerion Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Cyclerion Therapeutics.

Are investors shorting Cyclerion Therapeutics?

Cyclerion Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 776,000 shares, an increase of 6.3% from the December 15th total of 730,200 shares. Based on an average daily trading volume, of 844,100 shares, the short-interest ratio is presently 0.9 days. Approximately 3.0% of the shares of the stock are sold short. View Cyclerion Therapeutics' Current Options Chain.

Who are some of Cyclerion Therapeutics' key competitors?

What other stocks do shareholders of Cyclerion Therapeutics own?

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $3.58.

How big of a company is Cyclerion Therapeutics?

Cyclerion Therapeutics has a market capitalization of $98.34 million. View Additional Information About Cyclerion Therapeutics.

What is Cyclerion Therapeutics' official website?

The official website for Cyclerion Therapeutics is http://www.cyclerion.com/.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]


MarketBeat Community Rating for Cyclerion Therapeutics (NASDAQ CYCN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  19 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  41
MarketBeat's community ratings are surveys of what our community members think about Cyclerion Therapeutics and other stocks. Vote "Outperform" if you believe CYCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel